HC Wainwright Forecasts Strong Price Appreciation for Monopar Therapeutics (NASDAQ:MNPR) Stock

Monopar Therapeutics (NASDAQ:MNPR) had its price target lifted by equities research analysts at HC Wainwright from $22.00 to $40.00 in a report released on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s price target would suggest a potential upside of 1.73% from the company’s current price. HC Wainwright also issued estimates for Monopar Therapeutics’ FY2029 earnings at $3.66 EPS.

Several other equities analysts also recently issued reports on the company. Piper Sandler assumed coverage on Monopar Therapeutics in a research report on Friday, January 10th. They issued an “overweight” rating and a $72.00 price objective for the company. Rodman & Renshaw started coverage on Monopar Therapeutics in a report on Friday, October 11th. They issued a “buy” rating and a $50.00 price target for the company.

Monopar Therapeutics Stock Performance

MNPR opened at $39.32 on Wednesday. The firm has a market cap of $239.85 million, a price-to-earnings ratio of -19.96 and a beta of 1.23. The firm’s 50-day simple moving average is $23.76 and its 200-day simple moving average is $12.15. Monopar Therapeutics has a twelve month low of $1.54 and a twelve month high of $39.99.

Monopar Therapeutics (NASDAQ:MNPR) last posted its quarterly earnings data on Friday, November 8th. The company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.46) by $0.09. As a group, sell-side analysts anticipate that Monopar Therapeutics will post -1.65 EPS for the current fiscal year.

Insider Activity

In other news, CFO Karthik Radhakrishnan purchased 1,550 shares of the firm’s stock in a transaction that occurred on Monday, October 28th. The shares were acquired at an average price of $16.25 per share, for a total transaction of $25,187.50. Following the completion of the acquisition, the chief financial officer now directly owns 1,550 shares in the company, valued at approximately $25,187.50. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 34.90% of the company’s stock.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.